Chronic Kidney Disease
Chronic Kidney Disease
Part of NephTimes
Advertisement
Victoria SochaChronic Kidney Disease | March 4, 2024
Researchers studied the association between adolescent BMI and early CKD in young adulthood.
Read More
Victoria SochaChronic Kidney Disease | February 15, 2024
Anemia associated with CKD can be treated with oral hypoxia-inducible factor prolyl hydroxylase inhibitors.
Victoria SochaDiabetes and Hypertension | February 5, 2024
Patients with diabetic kidney disease face increased risk of end-stage kidney disease and dialysis.
Victoria SochaChronic Kidney Disease | February 5, 2024
Serum creatinine-based eGFR (eGFRcr) remains inaccurate and can overestimate eGFR, particularly in patients with sarcopenia.
Victoria SochaDiabetes and Hypertension | February 5, 2024
Strategies for the accurate evaluation of the risk of fragility fractures in elderly patients in the early stages of DKD.
Victoria SochaChronic Kidney Disease | February 5, 2024
More negative values of the differences between eGFRcysC and eGFRScr were associated with poor health-related quality of life
Victoria SochaAnemia and Kidney Disease | February 5, 2024
Patients with early chronic kidney disease (CKD) frequently develop anemia.
Victoria SochaHyperkalemia | February 5, 2024
The prevalence of hyperkalemia among individuals with chronic kidney disease (CKD) is 14% to 20%.
Victoria SochaHyperkalemia | February 5, 2024
Examining the effects of finerenone doses in patients with chronic kidney disease (CKD) and type 2 diabetes.
Dr. Richard LafayetteChronic Kidney Disease | February 5, 2024
Dr. Richard Lafayette discusses the FDA approval of TARPEYO, which reduces the loss of kidney function in IgA nephropathy.
Victoria SochaChronic Kidney Disease | February 5, 2024
When dietary potassium intake was examined within quartiles, there was a nonlinear association with AAC.
Victoria SochaHyperkalemia | February 5, 2024
Both hyperkalemia and hypokalemia are associated with muscle paralysis and potentially fatal cardiac arrhythmias.
Victoria SochaAnemia and Kidney Disease | February 5, 2024
The primary efficacy end point of interest was the mean change in hemoglobin from baseline over weeks 12 to 16.
Victoria SochaAnemia and Kidney Disease | February 5, 2024
Trials included in the analysis compared HIF-PHIs to placebo or to erythropoiesis-stimulating agents (ESA).
Victoria SochaChronic Kidney Disease | February 5, 2024
Development and validation of a model to predict future trajectories in eGFR in adults with type 2 diabetes and CKD.
Victoria SochaChronic Kidney Disease | February 5, 2024
A 2004 landmark study demonstrated an association between chronic kidney disease and an increased risk of CV events.
Victoria SochaDiabetes and Hypertension | February 5, 2024
Albuminuria is a strong determinant of kidney and cardiovascular risk in those with and without type 2 diabetes.
Victoria SochaHyperkalemia | February 5, 2024
There is an independent association between hyperkalemia and poor outcomes among individuals with chronic kidney disease.
Victoria SochaASN Kidney Week 2023 | February 5, 2024
There are few data available on CKD-MBD among patients receiving peritoneal dialysis.
Victoria SochaASN Kidney Week 2023 | February 5, 2024
Examining the potential benefits of pegloticase treatment in patients with CKD with refractory gout.
Advertisement
Advertisement
Advertisement
Latest News

March 1, 2024